IONTAS’ management have published high impact research papers on many core technology advances in antibody drug discovery.

39 Results Found

Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo

Publication: Oncotarget. March 2016, 29 (7): 16773-92 PMID: 26934448.

Authors: Botkjaer KA, Kwok HF, Terp MG, Karatt-Vellatt A, Santamaria S, McCafferty J, Andreasen PA, Itoh Y, Ditzel HJ, Murphy G

The INNs and outs of antibody nonproprietary names.

Publication: MAbs. January 2016, 8 (1): 1-9 PMID: 26716992.

Authors: Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA,, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J,, Baker MP

Selection of Antibodies Interfering with Cell Surface Receptor Signaling Using Embryonic Stem Cell Differentiation

Publication: Methods Mol. Biol. January 2016. 1341: 111-32 PMID: 26036698.

Authors: Melidoni AN, Dyson, MR, McCafferty J

Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2)

Publication: Biochem. J. November 2015, 471 (3): 391-401 PMID: 26303525.

Authors: Santamaria S, Yamamoto K, Botkjaer K,, Tape C, Dyson MR, McCafferty J, Murphy G, Nagase H

Identification of optimal protein binders through the use of large genetically encoded display libraries

Publication: Curr . Opin. Chem. Biol.. June 2015. 26: 16-24 PMID: 25626152.

Authors: McCafferty J, Schofield D